Anthony D'Adamio is CLO & VP at Bioventus Inc. (BVS). They have made 2 open-market trades across 1 company since 2021, most recently 2026-04-10.
CIK 0001835184
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $13K since 2021, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BVS | 153,655 | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-04-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BVS | SELL · 10b5-1 | 2025-04-11 | 2025-04-15 | $7.57 | $22K | -3.3% | -14.8% | -11.3% |
| BVS | SELL · 10b5-1 | 2025-03-17 | 2025-03-18 | $9.75 | $25K | -5.6% | -18.3% | -31.0% |
| BVS | SELL · 10b5-1 | 2025-02-18 | 2025-02-20 | $10.19 | $45K | +0.6% | -3.1% | -35.2% |
| BVS | SELL · 10b5-1 | 2024-12-23 | 2024-12-26 | $10.53 | $123K | -11.7% | -7.3% | -15.9% |
| BVS | SELL · 10b5-1 | 2024-06-21 | 2024-06-25 | $5.57 | $33K | +11.2% | +36.4% | +108.1% |
| BVS | SELL · 10b5-1 | 2024-06-17 | 2024-06-21 | $5.84 | $132K | +4.2% | +30.3% | +105.1% |
| BVS | SELL · 10b5-1 | 2024-04-11 | 2024-04-15 | $4.75 | $15K | -12.5% | +36.6% | +48.4% |
| BVS | SELL · 10b5-1 | 2024-03-15 | 2024-03-20 | $5.46 | $17K | -12.3% | -22.1% | +1.2% |
| BVS | SELL · 10b5-1 | 2023-03-15 | 2023-03-16 | $1.39 | $5K | -9.3% | -25.0% | +135.7% |
| BVS | SELL | 2022-04-04 | 2022-04-05 | $11.19 | $358K | -8.1% | -30.3% | -45.8% |
| BVS | SELL · 10b5-1 | 2022-02-14 | 2022-02-15 | $11.99 | $16K | +4.3% | +12.8% | -31.5% |
| BVS | BUY | 2021-02-11 | 2021-04-05 | $13.00 | $13K | -3.7% | -8.1% | +8.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.